Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
10 evidence topics · 18 sources
Summary
Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.
Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.
Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.
Resmetirom: histologic nonresponse, 52-week data, and absence of stopping rules (EASL-EASD-EASO)
Semaglutide: histologic nonresponse at week 72 in ESSENCE and absence of predictors of response (AASLD)
No FDA-approved noninvasive test for selection or monitoring (AASLD)
Unverified clinical benefit of accelerated approvals, untested combinations, and no therapy for MASH cirrhosis (EASL-EASD-EASO research needs)
Combined resmetirom and semaglutide: not studied (AASLD and real-world US cohort)
“Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis rate of the treatment-eligible US population (Madrigal-funded population calculator)
“Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world resmetirom access: prior authorization, denials, and dispensing delays at a US tertiary center
“Among the 137 patients prescribed resmetirom, 129 patients (94.2%) required insurance prior authorization. A total of 33 (24.1%) insurance prior authorization denials were seen, which required an appeal for insurance approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appeals were denied due to unmet biopsy requirements, expired noninvasive fibrosis testing, or complete plan exclusions. On average, resmetirom was dispensed 22.7 days after being prescribed, with a delay of 12.5 days after insurance approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite insurance approvals, access challenges persisted, with 5 patients discontinuing treatment prematurely due to cost concerns when nonprofit foundation grants were unavailable or logistical issues with specialty pharmacy dispensing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world resmetirom discontinuation in a US hepatology prescription pathway
“Thirteen patients (16%) discontinued resmetirom after an average of 25.5 days (range: 2–68 d), with 11 patients discontinuing due to adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One in 6 patients discontinued resmetirom, primarily due to side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote